Skip to main content
Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
1.160
-0.030 (-2.52%)
Nov 22, 2024, 4:00 PM EST - Market closed

Spero Therapeutics Revenue

Spero Therapeutics had revenue of $13.47M in the quarter ending September 30, 2024, a decrease of -47.12%. This brings the company's revenue in the last twelve months to $106.46M, up 37.01% year-over-year. In the year 2023, Spero Therapeutics had annual revenue of $103.78M with 93.95% growth.

Revenue (ttm)
$106.46M
Revenue Growth
+37.01%
P/S Ratio
0.58
Revenue / Employee
$2,314,239
Employees
46
Market Cap
63.24M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023103.78M50.27M93.95%
Dec 31, 202253.51M35.25M193.10%
Dec 31, 202118.26M8.93M95.67%
Dec 31, 20209.33M-8.82M-48.59%
Dec 31, 201918.15M14.18M357.56%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Procaps Group 414.10M
InterCure 72.42M
Exagen 55.75M
Celularity 42.69M
electroCore 23.33M
Hyperfine 13.26M
Cue Biopharma 9.53M
Monogram Technologies 365.00K
Revenue Rankings

SPRO News

More News